AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04032405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+CTG+i-prf
Description: combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
Study NCT04881474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: 30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.
Study NCT01221870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel once every 3 weeks
Description: Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
Study NCT01221870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel once weekly
Description: Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
Study NCT03347110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab at a prespecified dose.
Study NCT04378972 — intervention group
Intervention type: OTHER
Intervention: curcumin, homotaurine, vitamin D3
Description: ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.
Study NCT04378972 — intervention group
Intervention type: OTHER
Intervention: control
Description: ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
Study NCT02111798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
Study NCT02111798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL
Description: Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
Study NCT02111798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abstinence Initiation
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
Study NCT02111798 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Abstinence Initiation
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
Study NCT02111798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
Study NCT02111798 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relapse Prevention
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
Study NCT00114140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrent chemoradiotherapy temozolomide given 75 mg/m\^2 daily during radiotherapy for 6 weeks.~Post-Radiation Temozolomide given 150 mg/m2 daily on days 1-5 every 28 days with cycle one beginning 28 days post-radiotherapy. In the absence of grade 3 or 4 adverse events, a single dose escalation to 200 mg/m2/day could be attempted for cycle 2 and, if tolerated, that dose should continue for all subsequent cycles. Cycles were repeated every 28 days (+/- 2 days) for a total of 12 cycles.
Study NCT00114140 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: One treatment of 1.8 Gy given daily, 5 days per week (over 6 weeks) for a total dose of 54.0 Gy.
Study NCT01368497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and peginterferon
Description: Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
Study NCT01803698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in the use of IOM charts
Study NCT03531775 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upright MRI
Description: Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
Study NCT02662387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External nasal dilator (END)
Description: Applying External nasal dilator as adjuvant to high flow oxygen
Study NCT02662387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Description: Non-invasive positive pressure ventilation
Study NCT02662387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Description: Non-invasive positive pressure ventilation
Study NCT01000051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
Study NCT01000051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day, orally for 8 weeks.
Study NCT00947622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial Direct current stimulation
Study NCT00947622 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial Direct current stimulation
Study NCT04439240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor AZD4547
Description: Given PO
Study NCT01772498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Study NCT00710502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal NOTES cholecystectomy
Description: Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
Study NCT00710502 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
Study NCT02644967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
Study NCT02644967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
Study NCT03667339 — intervention group
Intervention type: PROCEDURE
Intervention: Direct Anterior Total Hip Arthroplasty
Description: Direct Anterior Total Hip Arthroplasty
Study NCT03814694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CRHP Diet
Description: Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
Study NCT03814694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CD Diet
Description: Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
Study NCT02765997 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unmanipulated UCB
Description: Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
Study NCT02765997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SR-1 UCB
Description: SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
Study NCT00471679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol
Study NCT02323412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin (Amoksicillintrihydrat)
Description: Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
Study NCT02323412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 1x3 for 100 days (oral intake).
Study NCT01560975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish®
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study NCT01400477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMXB-A-SR
Description: Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
Study NCT01400477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT03582462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS FXI-LRx
Description: Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
Study NCT03582462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
Study NCT01228201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous training
Description: Three training sessions per week in a total of 12 weeks
Study NCT01228201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: Three training sessions per week in a total of 12 weeks
Study NCT02816736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696
Description: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively.
Study NCT02816736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).
Study NCT02816736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696 placebo
Description: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
Study NCT02816736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan placebo
Description: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
Study NCT01291927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreas-sparing duodenectomy
Description: Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
Study NCT01291927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Description: The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
Study NCT01314924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: 70% cocoa
Study NCT02714049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sex therapy
Description: 60 minutes each time, in person or on the telephone
Study NCT02714049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
Study NCT02867605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Hyaluronan
Study NCT03551470 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic one-stage colorectal and liver resection
Study NCT01593618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UMFollowUp
Description: Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
Study NCT01593618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
Study NCT02889159 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Candida albicans antigen
Description: 0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
Study NCT02889159 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: histamine phosphate
Description: 0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
Study NCT02889159 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: imiquimod 5% cream
Description: Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
Study NCT01357382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
Study NCT06103656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Chinese Herbal Medication
Description: Capsules, 26 month course, starting 2 months pre-OIT.
Study NCT02889159 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tape Stripping
Description: At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
Study NCT01271543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
Study NCT01271543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation
Description: General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
Study NCT01994512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression without fusion
Description: Decompressive surgery of both central and lateral component of the stenosis.
Study NCT04840381 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire administrations
Description: Administration of an ad hoc questionnaire to register food frequency consumption and meal time, main recipes; phisical activity questionnaire and list of questions concerning the previous and actual health status of participants
Study NCT01994512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression with fusion
Description: Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
Study NCT00286949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atomoxetine
Description: Open Label uncontrolled active Drug intervention
Study NCT01601834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340 or Placebo
Description: PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
Study NCT00401336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging multiecho gradient-echo sequence
Description: Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
Study NCT05440682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CP group
Description: Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
Study NCT04054648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bedtime administration of the participant's pre-existing antihypertensive medications
Description: Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.